Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC
Artículo
Acceso abierto
Artículo
DOAJ
Background & Aims: Atezolizumab/bevacizumab (A/B) and durvalumab ± tremelimumab (DT/D) are preferred first-line regimens for the treatment of hepatocellular carcinoma (HCC). Although both therapies share an anti-PD-...
LCC LCC:Diseases of the digestive system. GastroenterologyIdioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access